← Leaderboards
Milan Patel
Pathogendx
$9,509,761
Attributed
$9,509,761
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.9M · FY2021–22$10M$7.5M$5M$2.5M$0
'21
'22
Funding mix
By agency
NIH$9,509,761 · 1
By mechanism
N02$9,509,761 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Cost”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Scott Topper · Broad Institute, Inc.$77,958,806
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Mark Marino · Venturewell$48,913,644
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,367,817
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
Research focus
CostCost SavingsCovid-19ExercisePerformance At WorkQuantitative Reverse Transcriptase PcrRadxRadx TechSlideTechnologyUpdateVariant Detection
Grant awards (2)
TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE$590,553
N02 · FY2022 · HL · contact PI
TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE$8,919,208
N02 · FY2021 · HL · contact PI